The TargoPep Platform

Our delivery innovations will empower oligonucleotide therapeutics to reach the clinic

TargoPep combines a unique and bespoke delivery design, with a mild and facile attachment approach which, when combined with an active oligo- therapeutic, can be iteratively improved and adjusted to fit a disease profile.

Our delivery innovations will empower oligonucleotide therapeutics to reach the clinic ​

TargoPep combines a unique and bespoke delivery design, with a mild and facile attachment approach which, when combined with an active oligo- therapeutic, can be iteratively improved and adjusted to fit a disease profile.

TargoPep Advanced Delivery Peptides (ADPs) enable effective delivery with low toxicity and high stability

TargoPep has moved beyond the previous reliance on natural substrates and brings together the ‘Lipinski world’ with biologics – treating each amino acid building block separately and establishing its drug-like principals. 

Modulating key properties such as basicity (how positively charged), denticity (how many grip points) and lipophilicity (how greasy), TargoPep uses these properties to interact with specific cell surfaces more strongly and pass the cell membrane more effectively.

Simple, gentle and specific integration with oligonucleotide therapeutics

With biocompatible, controllable and mild solutions to attach TargoPep ADPs, these short enabling sequences can be simply integrated with all current oligonucleotide therapeutics with minimal modifications.

The adaptable nature of TargoPep ADP structures alongside facile therapeutic attachment enables a variety of solutions to be generated and refined dynamically to provide the best solution for specific diseases.

TargoPep is advancing unmet clinical needs in NF1 and Parkinson's disease

TargoPep is applying its delivery platform to a wide variety of therapeutic oligonucleotide modalities, all focused on providing cures to neurofibromatosis type 1 and Parkinson’s disease.

Using morpholino oligomers, siRNA and gapmers we are modulating and re-writing disease bearing proteins bringing real world improvements to patients’ lives.  

TargoPep ADPs can enhance the delivery of other therapeutics, as well as that of oligonucleotide therapies

 

The wide and tuneable palette that TargoPep has developed, plus our mild attachment methods, empower us to build idealised delivery solutions for collaborative projects.

TargoPep is currently collaborating with the Nucleic Acid Therapy Accelerator (NATA) which has the potential to develop cellular/output models for a range of delivery targets.